Abstract:PARP1 is one of six enzymes required for the highly error-prone DNA repair pathway microhomology-mediated end joining (MMEJ) and needs to be inhibited when over-expressed. In order to study the PARP1 inhibitory effect of fused tetracyclic or pentacyclic dihydrodiazepinoindolone derivatives (FTPDDs) by quantitative structure-activity relationship technique, six models were established by four kinds of methods, heuristic method, gene expression programming, random forester, and support vector regression with single, double, and triple kernel function respectively. The single, double, and triple kernel functions were RBF kernel function, the integration of RBF and polynomial kernel functions, and the integration of RBF, polynomial, and linear kernel functions respectively. The problem of multi-parameter optimization introduced in the support vector regression model was solved by the particle swarm optimization algorithm. Among the models, the model established by support vector regression with triple kernel function, in which the optimal R 2 and RMSE of training set and test set were 0.9353, 0.9348 and 0.0157, 0.0288, and R 2 cv of training set and test set were 0.9090 and 0.8971, shows the strongest prediction ability and robustness. The method of support vector regression with triple kernel function is a great promotion in the field of quantitative structure-activity relationship, which will contribute a lot to designing and screening new drug molecules. The information contained in the model can provide important factors that guide drug design. Based on these factors, six new FTPDDs have been designed. Using molecular docking experiments to determine the properties of new derivatives, the new drug was ultimately successfully designed.

Qsar Models For Phosphoramidate Prodrugs Of 2 '-Methylcytidine As Inhibitors Of Hepatitis C Virus Based On Pso Boosting

QSAR Research of Novel Tetrandrine Derivatives Against Human Hepatocellular Carcinoma.

Activity prediction of hepatitis C virus NS5B polymerase inhibitors of pyridazinone derivatives

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

QSAR study of thiocarbamates as non-nucleoside HIV-1 reverse transcriptase in hibitors

The index of ideality of correlation: QSAR studies of hepatitis C virus NS3/4A protease inhibitors using SMILES descriptors

Boosting: An Ensemble Learning Tool for Compound Classification and QSAR Modeling

Discovery of 2′-Α-c-methyl-2′-β-c-fluorouridine Phosphoramidate Prodrugs As Inhibitors of Hepatitis C Virus

Predicting Anti‐HIV‐1 Activities of HEPT‐analog Compounds by Using Support Vector Classification

Phosphoramidate Protides of 2 '-C-methylguanosine As Highly Potent Inhibitors of Hepatitis C Virus. Study of Their in Vitro and in Vivo Properties

Synchronous spectrofluorimetry and chemometric modeling: A synergistic approach for analyzing simeprevir and daclatasvir, with application to pharmacokinetics evaluation

Insight into the structural requirements of benzothiadiazine scaffold-based derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics

Pharmacophore Model and 3D-QSAR Study of Two Kinds of HCVNS3 Serine Protease Inhibitors

Classification of 5-Ht1a Receptor Ligands on the Basis of Their Binding Affinities by Using Pso-Adaboost-Svm

3D-QSAR Analysis of Sialyltransferase Inhibitors

2D-QSAR, docking, molecular dynamics, studies of PF-07321332 analogues to identify alternative inhibitors against 3CLpro enzyme in SARS-CoV disease

Study of PARP inhibitors for breast cancer based on enhanced multiple kernel function SVR with PSO

A Linear and Nonlinear QSAR Analysis of Benzimidazole Derivative XY123 in Prostate Cancer Treatment

QSAR Studies of Imidazopyridine Derivatives As Et-PKG Inhibitors Using the PSO-SVM Approach

A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity

Combined 3D-QSAR, Molecular Docking and Molecular Dynamics Study on the Benzimidazole Inhibitors Targeting HCV NS5B Polymerase